@article{171e098602ac4b72b517bb443cd0a774,
title = "Comment: Sensitivity and clinical relevance of available anti-aquaporin-4 antibody assays",
author = "Kazuo Fujihara",
note = "Funding Information: Disclosure: Prof. Fujihara serves/has served on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, and Merck Serono; has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec, Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, and Asahi Kasei Kuraray Medical Co., Ltd.; serves on the editorial board of Clinical and Experimental Neuroimmunology; receives publishing royalties from Clinical Practice Guide of Orthopedic Surgery (Bunkodo, 2007); and receives/has received research support from Bayer Schering Pharma, Eisai Inc., Kowa Pharmaceuticals America, Inc., Biogen Idec, Asahi Kasei Kuraray Medical Co., Ltd., The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN), Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma, Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan, and Grants-in-Aid for Scientific Research from the Ministry of Health, Welfare and Labor of Japan. ",
year = "2012",
month = feb,
day = "28",
doi = "10.1212/WNL.0b013e318248df85",
language = "English",
volume = "78",
pages = "669",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",
}